Author:
Smith T.J.,Coyne P.J.,Staats P.S.,Deer T.,Stearns L.J.,Rauck R.L.,Boortz-Marx R.L.,Buchser E.,Català E.,Bryce D.A.,Cousins M.,Pool G.E.
Reference22 articles.
1. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence;Meuser;severity and etiology. Pain,2001
2. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity;Smith;and survival. J Clin Oncol,2002
3. Management of Cancer Pain. Clinical Practice Guideline No. 9;Jacox,1994
4. What is the evidence of the implantable drug delivery systems for refractory cancer pain?;Smith;Support Cancer Ther,2004
5. The implantable drug delivery trial group preliminary estimates of the cost effectiveness (CE) ratio of implantable drug delivery systems (IDDS) compared to comprehensive medical management (CMM) in patients with refractory cancer pain;Hillner;Proc Am Soc Clin Oncol,2003
Cited by
155 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献